Pharmacotherapy versus T lymphocytes for CMV

Helen E. Heslop

doi:10.1182/blood-2013-03-487249

Pharmacotherapy versus T lymphocytes for CMV

Helen E. Heslop

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV) - specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.

Original language	English (US)
Pages (from-to)	3544-3545
Number of pages	2
Journal	Blood
Volume	121
Issue number	18
DOIs	https://doi.org/10.1182/blood-2013-03-487249
State	Published - May 2 2013

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2013-03-487249

Cite this

@article{5a54a4097f534334b1683bbb47c467c3,

title = "Pharmacotherapy versus T lymphocytes for CMV",

abstract = "In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV) - specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.",

author = "Heslop, {Helen E.}",

year = "2013",

month = may,

day = "2",

doi = "10.1182/blood-2013-03-487249",

language = "English (US)",

volume = "121",

pages = "3544--3545",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "18",

}

TY - JOUR

T1 - Pharmacotherapy versus T lymphocytes for CMV

AU - Heslop, Helen E.

PY - 2013/5/2

Y1 - 2013/5/2

N2 - In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV) - specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.

AB - In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV) - specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.

UR - http://www.scopus.com/inward/record.url?scp=84879720192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879720192&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-03-487249

DO - 10.1182/blood-2013-03-487249

M3 - Comment/debate

C2 - 23640995

AN - SCOPUS:84879720192

SN - 0006-4971

VL - 121

SP - 3544

EP - 3545

JO - Blood

JF - Blood

IS - 18

ER -

Pharmacotherapy versus T lymphocytes for CMV

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this